Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

BACKGROUND: The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). METHODS: Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839215/
https://ncbi.nlm.nih.gov/pubmed/33499913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02388-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky